Latest news

Bioservo has completed a directed issue of approximately SEK 14 million (regulatory information)

Bioservo is investigating the prerequisites for carrying out a directed share issue (regulatory information)

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies


17 Sep, 2020  ·  Regulatory information

Loxam has placed orders for 18 Ironhand® systems

Loxam has placed orders for 18 Ironhand® systems at an order value of MSEK 1.2. The systems will improve the availability and cater for the increased need from Loxam customers at additional rental sites in France.

Loxam and Bioservo signed an exclusive rental agreement in December 2019, an agreement that allows Loxam to offer Ironhand® for rental all over France. The orders for the 18 Ironhand® systems, including consumables and accessories will be delivered in September and the Ironhand® system will be available for rental at 17 rental sites all over France.

“The order confirms the increased interest in Ironhand® we notice from both France and other countries. The workers within the construction and manufacturing industries often performs repetitive tasks for a long period of time and may be at risk of developing strain injuries. We are really happy that Ironhand® are made available to more and more workers all across France.”, says Petter Bäckgren, CEO Bioservo.


For more information, please contact
Petter Bäckgren, CEO of Bioservo Technologies AB
Phone: +46 (0)8 21 17 10

Mikael Wester, Marketing Director of Bioservo Technologies AB
Phone: +46 (0)8 21 17 10


About Bioservo Technologies
Bioservo Technologies AB (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimize the body’s endurance and performance, or for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8 528 00399, is the Company’s Certified Adviser on Nasdaq First North Growth Market.

For more information, please visit